Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression

• Main Authors: Stefan Wagner (Author), Daniel I. Brierley (Author), Alasdair Leeson-Payne (Author), Wanqing Jiang (Author), Raffaella Chianese (Author), Brian Y.H. Lam (Author), Georgina K.C. Dowsett (Author), Claudia Cristiano (Author), David Lyons (Author), Frank Reimann (Author), Fiona M. Gribble (Author), Pablo B. Martinez de Morentin (Author), Giles S.H. Yeo (Author), Stefan Trapp (Author), Lora K. Heisler (Author)
• Format: Book
• Published: Elsevier, 2023-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Overweight and obesity are endemic in developed countries, with a substantial negative impact on human health. Medications developed to treat obesity include agonists for the G-protein coupled receptors glucagon-like peptide-1 (GLP-1R; e.g. liraglutide), serotonin 2C (5-HT2CR; e.g, lorcas...